Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in SwedenShow others and affiliations
2019 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301, Vol. 15, no 23, p. 2733-2741Article in journal (Refereed) Published
Abstract [en]
Aim: We aimed to describe the use of subcutaneous (sc.) trastuzumab use in a real-world setting.
Patients & methods: This retrospective cohort study evaluated electronic medical records of patients with early breast cancer and trastuzumab use from January 2010 to February 2018 in three hospitals in Sweden.
Results: In total, 363 patients received trastuzumab during study period. Of these, 217 (59.8%) patients started treatment with sc. trastuzumab and 146 (40.2%) with intravenous trastuzumab. After sc. trastuzumab approval, use of sc. trastuzumab increased from 70.2% in 2014 to 100% in 2017. Since 2013, 34 of 35 (97.4%) patients who started with intravenous trastuzumab switched to sc. formulation.
Conclusion: Trastuzumab sc. quickly became the prevailing formulation for treatment in HER2-positive early breast cancer.
Place, publisher, year, edition, pages
Future Medicine Ltd. , 2019. Vol. 15, no 23, p. 2733-2741
Keywords [en]
HER2-positive, breast cancer, real-world setting, subcutaneous, trastuzumab
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-75589DOI: 10.2217/fon-2019-0160ISI: 000489271200007PubMedID: 31306041Scopus ID: 2-s2.0-85071163011OAI: oai:DiVA.org:oru-75589DiVA, id: diva2:1343512
Note
Funding Agency:
Hoffmann-La Roche
2019-08-162019-08-162024-03-05Bibliographically approved